Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Radioimmunotherapy (II): Clinical Application

방사면역치료(II): 임상적 이용

  • Cheon, Gi-Jeong (Departments of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Kang, Hye-Jin (Departments of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences) ;
  • Lim, Sang-Moo (Departments of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences)
  • Published : 2006.04.29
Download PDF
⟨ Previous Next ⟩

Abstract

Molecular targeting may be defined as the specific concentration of a diagnostic or therapeutic tracer by its Interaction with a molecular species that is distinctly present or absent in a disease state. Monoclonal antibody (mAb) is one of the successful agents for targeted therapy in cancer. To enhance the therapeutic effect, the concept of targeting radionuclides to tumors using radiolabeled mAbs against tumor-associated antigens, radioimmunotherapy, was proposed. The efficacy of radioimmunotherapy, however, has to be further optimized. Several strategies to improve targeting of tumors with radiolabeled mAbs have been developed, such as the use of mAb fragments, the use of high-affinity mAbs, the use of labeling techniques that are stable in vivo, active removal of the radiolabeled mAb from the circulation, and pretargeting strategies. Until now, however, there are many kinds of obstacles to be solved in the use of mAb for the targeted therapy. Major technical challenges to molecular targeting are related to the rapid and specific delivery of tracers to the target, the elimination of unwanted background activity, and the development of more specific targets to create a cytocidal effect. further development of this field will be determined by success in solving these challenges.

Keywords

References

  1. Bethge WA, Sandmaier BM. Targeted Cancer Therapy and Immunosuppression Using Radiolabeled Monoclonal Antibodies. Semin Oncol 2004;31:68-82 https://doi.org/10.1053/j.seminoncol.2003.11.004
  2. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713
  3. Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 2001;45:201-6
  4. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300 https://doi.org/10.1042/bj3200293
  5. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66
  6. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40 https://doi.org/10.1126/science.1064126
  7. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;316:265-8 https://doi.org/10.1038/316265a0
  8. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20B-cell lymphoma: long term follow-up of a phase I/II study. Blood 2004;103:4429-31 https://doi.org/10.1182/blood-2003-11-3883
  9. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with $^{90}$Y ibritumomab tiuxetan (zevalin). Semin Oncol 2003; 30(suppl):6-10
  10. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66
  11. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39:181-94 https://doi.org/10.1016/S1040-8428(01)00107-X
  12. Liu CB, Liu GZ, Liu N, et al. Radiolabeling morpholinos with $^{90}$Y, $^{111}$In, $^{188}$Re and $^{99m}$Tc. Nucl Med Biol 2003;30:207-14 https://doi.org/10.1016/S0969-8051(02)00389-X
  13. McQuarrie SA, Xiao Z, Miller GG, Mercer JR, Suresh MR. Modern trends in radioimmunotherapy of cancer: pretargeting strategies for the treatment of ovarian cancer. Q J Nucl Med 2001;45:160-6
  14. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm 2000;15:347-55 https://doi.org/10.1089/cbr.2000.15.347
  15. Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med 2003;44:1541-3
  16. Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm 2003;18:393-404 https://doi.org/10.1089/108497803322285134
  17. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9
  18. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46
  19. Meredith RF, Khazaeli MB, Macey DJ, et al. Phase II study of interferonenhanced $^{131}$I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999;5:3254S-8S
  20. Meredith RF, Khazaeli MB, Plott WE, et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996;2:1811-8
  21. Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6:3095-102
  22. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003;102:2351-7 https://doi.org/10.1182/blood-2003-02-0622
  23. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999;14:153-66 https://doi.org/10.1089/cbr.1999.14.153
  24. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44:400-11
  25. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-63
  26. Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777-80 https://doi.org/10.1007/s00259-002-1089-6
  27. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435-50 https://doi.org/10.1016/S0734-9750(01)00065-9
  28. Liu G, He J, Dou S, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004;31:417-24 https://doi.org/10.1007/s00259-003-1393-9
  29. Liu G, Liu C, Zhang S, et al. Investigations of 99mTc morpholino pretargeting in mice. Nucl Med Commun 2003;24:697-705 https://doi.org/10.1097/00006231-200306000-00013
  30. Paganelli G, Chinol M. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6 https://doi.org/10.1007/s00259-002-1090-0
  31. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidinbiotin system. Int J Biol Markers 1993;8:155-9 https://doi.org/10.1177/172460089300800304
  32. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6
  33. Paganelli G, Pervez S, Siccardi AG, et al. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 1990;45:1184-9 https://doi.org/10.1002/ijc.2910450632
  34. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalentbispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003;9:3886S-96S
  35. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503 https://doi.org/10.1146/annurev.med.55.091902.104249
  36. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 15;20:2453-63 https://doi.org/10.1200/JCO.2002.11.076
  37. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF.$^{131}$I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513-24 https://doi.org/10.1089/108497803322287583
  38. Goldenberg, DM. Therapeutic use of radiolabeled antibodies: hematopoietic tumors. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd ed. London, UK: Churchill Livingstone; 2004:428-34
  39. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9:3991S-4S
  40. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004;103:1485-94 https://doi.org/10.1182/blood-2003-06-2037
  41. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-1302
  42. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447-54
  43. Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with 111indium, 67gallium, or 90yttrium. Clin Cancer Res 2001;7:1505-10
  44. Pressman D, Korngold L. The in vivo localization of anti-wagner osteogenicsarcoma antibodies. Cancer 1953;6:619-23 https://doi.org/10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y
  45. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine- 131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 1997;15:1518-28 https://doi.org/10.1200/JCO.1997.15.4.1518
  46. Wong JY, Shibata S, Williams LE, et al. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52
  47. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991;51:6650-5
  48. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70 https://doi.org/10.1200/JCO.2005.18.622
  49. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl):115S-27S
  50. Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen- producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5(suppl): 3183S-9S
  51. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti- carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003;9:3973S-81S